Document is current
Any future updates will be listed below
-
Authors
Amigó, Núria
Castelblanco, Esmeralda
Julve, Josep
Martínez-Micaelo, Neus
Alonso, Núria
Hernández, Marta
Ribalta, Josep
Guardiola, Montse
Torán-Monserrat, Pere
Lopez-Lifante, Victor
Herrero-Alonso, Cecilia
Arteaga, Ingrid
Ortega, Emilio
Franch-Nadal, Josep
Mauricio, Didac
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI15/0625, PI15/0625)
- License Information
-
More Information
Article History
Received: 30 November 2024
Accepted: 6 February 2025
First Online: 21 February 2025
Declarations
:
: The study protocol for the LIPOCAT Study was approved by the Ethics Committees of University Hospital Germans Trias i Pujol (PI-18–039). The associated cohorts were previously approved by the Ethics Committees of University Hospital Arnau de Vilanova (CEIC-1571, Diabetes Mellitus study), Ethics and Clinical Investigation Committee of IDIAP Jordi Gol (P16/014, ARTPER; P11/58, FIBROSCAN), Hospital Clinic of Barcelona (Clinic cohort ClinicalTrials.gov Identifier: NCT01898572, DIABIMCAP Study), and Carlos Haya Hospital (Di@bet.es), and all participants were duly informed about the study protocols and provided their consent to participate.
: Not applicable.
: N. Amigó is a stock owner of Biosfer Teslab and has a patent of the lipoprotein profiling described in the present manuscript. Prof. Mauricio is a co-author of this study and an Editorial Board member of the Cardiovascular Diabetology journal. He did not participate in handling this manuscript during the submission or review processes. The rest of the authors declare that they have no competing interests.
